Consensus Incyte Corporation

Stocks

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq 00:00:00 24/10/2026 +04			5-day change	1st Jan Change
115.71 ^USD	-1.04%		+2.33%	+17.15%

11:38am	Genmab, Incyte Sign Colorectal Cancer Trial Collaboration for Colorectal Cancer Treatment	MT
08:51am	Genmab Partners with Incyte on Clinical Trial for Metastatic Colorectal Cancer Treatment	MT

Evolution of the Average Target: Incyte Corporation

Evolution of the Target Price: Incyte Corporation

Changes in Analyst Recommendations: Incyte Corporation

df26778a7746e.jNBh41Ney0EcJPy-Akapi2TIspYqQhINplZp56eWVHo.-roVkRQLoCNLYbPPZS_TxR6x07tzID9L5TEf0ZCmIkL6pjCpYj3yCUxFmw~3fd73209943f78e01a88279d6c3d2f92

Analysts' recommendations: Incyte Corporation

10-22	Leerink Partners Adjusts Price Target on Incyte to $154 From $155	MT
10-21	TD Cowen Adjusts Price Target on Incyte to $140 From $138	MT
10-15	Goldman Sachs Adjusts Price Target on Incyte to $117 From $118	MT
10-14	Truist Raises Price Target on Incyte to $115 From $105, Keeps Hold Rating	MT
10-08	RBC Lifts Price Target on Incyte to $114 From $109, Keeps Sector Perform Rating	MT
10-05	Stifel Adjusts Price Target on Incyte to $157 From $145, Keeps Buy Rating	MT
10-01	Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating	MT
09-28	HC Wainwright Adjusts Price Target on Incyte to $152 From $150, Maintains Buy Rating	MT
09-28	JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Rating	MT
08-20	Canaccord Genuity Initiates Incyte at Buy With $152 Price Target	MT
08-17	Piper Sandler Adjusts Price Target on Incyte to $130 From $110, Maintains Overweight Rating	MT
08-13	Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating	MT
08-03	Mizuho Adjusts Price Target on Incyte to $137 From $121	MT
08-03	Leerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating	MT
07-31	Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating	MT
07-30	JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating	MT
07-29	Incyte's Solid Q2 Seen Funding Strategy Beyond Jakafi Patent Expiration, RBC Says	MT
07-29	TD Cowen Adjusts Incyte Price Target to $138 From $124, Maintains Buy Rating	MT
07-29	Barclays Adjusts Incyte Price Target to $139 From $134, Maintains Overweight Rating	MT
07-29	Morgan Stanley Adjusts Incyte PT to $119 From $104, Maintains Equal Weight Rating	MT
07-29	BMO Capital Adjusts Incyte Price Target to $130 From $112, Maintains Market Perform Rating	MT
07-29	Jefferies & Co Adjusts Incyte Price Target to $115 From $105, Maintains Hold Rating	MT
07-29	Guggenheim Adjusts Incyte Price Target to $150 From $136, Maintains Buy Rating	MT
07-29	HC Wainwright Raises Incyte Price Target to $150 From $140, Maintains Buy Rating	MT
07-29	Goldman Sachs Adjusts Incyte Price Target to $118 From $110, Maintains Neutral Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	INCYTE CORPORATION					+11.95%
	ELI LILLY AND COMPANY					+4.56%
	JOHNSON & JOHNSON					+5.91%
	ABBVIE INC.					-0.3%
	ROCHE HOLDING AG					-1.16%
	MERCK & CO., INC.					+9.97%
	NOVARTIS AG					-3.36%
	ASTRAZENECA PLC					+22.49%
	AMGEN INC.					-9.55%
	GILEAD SCIENCES, INC.					+2.66%
	Average					+4.32%
	Weighted average by Cap.					+3.83%